乙基4-氰基-2-氟苯甲酸酯 | 220389-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙基4-氰基-2-氟苯甲酸酯
• 英文名称: 4-cyano-2-fluoro-benzoic acid ethyl ester
• 英文别名: 4-cyano-2-fluorobenzoic acid ethyl ester；ethyl 4-cyano-2-fluorobenzoate
• CAS: 220389-15-1
• 化学式: C₁₀H₈FNO₂
• mdl: MFCD04343738
• 分子量: 193.177
• InChiKey: ZAAOWPGLLZUDHX-UHFFFAOYSA-N

物化性质

• 熔点：
  72.0-72.4 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  308.9±32.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙基4-氰基-2-氟苯甲酸酯 在 吡啶 、 lithium hydroxide 、 caesium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.75h， 生成 4-[4-(2-丁氧基乙氧基)-5-甲基-1,3-噻唑-2-基]-2-氟苯甲酸
  参考文献：
  名称：

  Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

  摘要：

  4'-Octyl-4-biphenylcarboxylic acid (1g, AC-55649) was identified as a highly isoform-selective agonist at the human RAR beta 2 receptor in a functional intact cell-based screening assay. The subsequent hit to lead optimization transformed the lipophilic, poorly soluble hit into a more potent and orally available compound (2, AC-261066) with retained beta 2 selectivity and greatly improved physiochemical properties. Being an isoform-selective RAR beta 2 receptor agonist that discriminates between nuclear receptor isoforms having identical ligand binding domains, 2 will be useful as a pharmacological research tool but also a valuable starting point for drug development.

  DOI：

  10.1021/jm050891r
• 作为产物：
  描述：

  4-氯-2-氟苯甲酸乙酯 生成 乙基4-氰基-2-氟苯甲酸酯
  参考文献：
  名称：

  N-acylamino acid amide compounds and intermediates for preparation thereof

  摘要：

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。

  公开号：

  US06265418B1

文献信息

• COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS
  申请人：Olsson Roger

  公开号：US20090176837A1

  公开（公告）日：2009-07-09

  Disclosed herein are novel compounds with activity at RARβ 2 receptors. Further disclosed are the use of such compounds for treatment of or to alleviate symptoms of cancer, neurological disorders such as memory deficits and schizophrenia, neurodegenerative disorders such as Parkinson's and Alzheimer's diseases, inflammatory disorders such as psoriasis and rheumatoid arthritis, eye disorders and depression.

  本文揭示了具有对RARβ 2受体活性的新化合物。进一步揭示了这些化合物的用途，用于治疗或缓解癌症、神经系统疾病（如记忆障碍和精神分裂症）、神经退行性疾病（如帕金森病和阿尔茨海默病）、炎症性疾病（如银屑病和类风湿性关节炎）、眼部疾病和抑郁症状。
• N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF
  申请人：UBE INDUSTRIES LIMITED

  公开号：EP1020467A1

  公开（公告）日：2000-07-19

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了式 (I) 所代表的化合物： 其中 A 代表下式（a-1）或下式（a-2）： B 代表下式（b）： (其中各符号如说明书中所定义）或其药学上可接受的盐类，以及用于制备它们的中间体，它们具有优异的血小板聚集抑制活性和其他特性，可用作与纤维蛋白原受体、血栓形成、梗塞等相关疾病的预防或治疗药物。
• WO2007/9083
  申请人：——

  公开号：——

  公开（公告）日：——
• Design, Synthesis, and Structure−Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands
  作者：Birgitte W. Lund、Anne Eeg Knapp、Fabrice Piu、Natalie K. Gauthier、Mikael Begtrup、Uli Hacksell、Roger Olsson

  DOI：10.1021/jm801532e

  日期：2009.3.26

  We recently discovered the isoform selective RAR beta 2 ligand 4'-octyl-4-biphenylcarboxylic acid (3, AC-55649). Although 3 is highly potent at RAR beta 2 and displays excellent selectivity, solubility issues make it unsuitable for drug development. Herein we describe the exploration of the SAR in a biphenyl and a phenylthiazole series of analogues of 3. This ultimately led to the design of 28, a novel, orally available ligand with excellent isoform selectivity for the RAR beta 2.
• HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1959951B1

  公开（公告）日：2009-12-23